PROCEPT BioRobotics (PRCT) Cash & Equivalents (2020 - 2026)

PROCEPT BioRobotics (PRCT) has reported Cash & Equivalents for 7 consecutive years, with $275.1 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash & Equivalents fell 9.13% year-over-year to $275.1 million in Q2 2026; TTM through Jun 2026 was $275.1 million, a 9.13% decrease from a year earlier, with the FY2025 full-year figure at $286.5 million, down 14.15% from the prior year.
• Cash & Equivalents was $275.1 million for Q2 2026 at PROCEPT BioRobotics, up from $245.6 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $333.7 million in Q4 2024 and troughed at $149.7 million in Q2 2023.
• A 5-year average of $255.0 million and a median of $263.5 million in 2022 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents jumped 230.11% in 2022 and plunged 44.52% in 2023, its largest moves.
• Over 5 years, Cash & Equivalents stood at $221.9 million in 2022, then grew by 15.94% to $257.2 million in 2023, then grew by 29.74% to $333.7 million in 2024, then dropped by 14.15% to $286.5 million in 2025, then decreased by 3.98% to $275.1 million in 2026.
• The last three Cash & Equivalents figures came in at $275.1 million (Q2 2026), $245.6 million (Q1 2026), and $286.5 million (Q4 2025), per Business Quant data.